Highly specific functional equivalence of XN-HPC for optimum CD34+ cell count in harvested allogeneic bone marrow stem cell products

Hematology. 2022 Dec;27(1):232-238. doi: 10.1080/16078454.2022.2030884.

Abstract

Objectives: To establish a reliable XN-HPC cutoff, for an effective CD34 + cell count of ≥2 × 106cells/kg of the recipient's body weight, in harvested bone marrow products in allogenic transplantation.

Methods: The study was carried out in two phases. In retrospective Phase 1, data from 47 donors were analyzed. Sysmex analyzer XN-20 and BD FACS Calibur were employed to process XN-HPC and CD34 + cell enumeration, respectively. To make the two variables comparable, both XN-HPC and CD34 + cell counts were reported as the number of cells/kg of the recipient's body weight. Spearman's rank correlation coefficient was calculated for CD34 + cells and XN-HPC, followed by the calculation of the receiver operating characteristic (ROC) curve to identify the XN-HPC value which could effectively predict the cutoff of ≥2 × 106 CD34 + cells/kg of the recipient's body weight. In Phase 2, the computed XN-HPC cutoff was validated in a prospective set of 53 donors by obtaining the positive and negative predictive values.

Results: Statistically significant correlation was obtained between XN-HPC and CD34 + cell count with Spearman's rho of 0.54 (p-value <0.001). The optimal XN-HPC cutoff, for the required CD34 + ve cell count of ≥2 × 106 cells/kg of the recipient's body weight, was calculated to be ≥2.80×106 cells/kg of the recipient's body weight with the specificity and sensitivity of 100% and 31%, respectively. The ROC curve demonstrated the area under the curve to be 0.74. Phase 2 validation revealed 100% PPV.

Conclusions: For harvested bone marrow products with XN-HPC of ≥2.80×106 cell/kg of the recipient's body weight, CD34 + cell enumeration by flow cytometry can safely be disposed of.

Keywords: CD34+ cell count; XN-HPC; allogeneic transplantation; autologous stem cell transplant; bone marrow harvesting; bone marrow transplantation; hematopoietic progenitor cells; hematopoietic reconstitution.

Publication types

  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Video-Audio Media

MeSH terms

  • Allografts
  • Antigens, CD34
  • Bone Marrow Cells*
  • Cell Count
  • Cell Separation*
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Male
  • Stem Cell Transplantation*
  • Stem Cells*
  • Tissue Donors*

Substances

  • Antigens, CD34